Clarus Therapeutics (CRXT) Announces 3.02M Share Private Placement at $4.96/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures tepid as Middle East tensions keep investors wary
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- Snowflake soars 20% on earnings beat and raised guidance
Clarus Therapeutics Announces $15 Million Private Placement
December 3, 2021 9:05 AM ESTProceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate)
NORTHBROOK, Ill., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it has entered into a definitive agreement to sell securities in a private placement with a leading healthcare investor. The gross proceeds to Clarus from the private placement, before deducting the placement agents fees and other estimated offering expenses payable by Clarus, are... More
